



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Jason D. Bannan et al.  
Serial No. : 09/335,581 Group Art Unit: 1645  
Filed : June 18, 1999 Examiner: N.M. Minnifield  
For : PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC SHOCK SYNDROME AND SEPTIC SHOCK

**LETTER REQUESTING TRANSFER  
OF COMPUTER READABLE FORM  
PURSUANT TO 37 CFR §1.821(e)**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

The paper copy of the Sequence Listing in this application 09/335,581 is identical to the computer readable copy of the Sequence Listing filed in parent application 08/838,413, filed April 7, 1997. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in a separately filed amendment (filed herewith) for incorporation into the specification.

Respectfully submitted,  
Morgan & Finnegan, L.L.P.

Dated: October 12, 2000

By

  
Mary J. Morry  
Registration No. 34,398

Mailing Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Ave.  
New York, NY 10154  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile



Application No.: 09/335581

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE.**